A Multistep In Silico Approach Identifies Potential Glioblastoma Drug Candidates via Inclusive Molecular Targeting of Glioblastoma Stem Cells
AbstractGlioblastoma (GBM) is the highest grade of glioma for which no effective therapy is currently available. Despite extensive research in diagnosis and therapy, there has been no significant improvement in GBM outcomes, with a median overall survival continuing at a dismal 15 –18 months. In recent times, glioblastoma stem cells (GSCs) have been identified as crucial drivers of treatment resistance and tumor recurrence, and GBM therapies targeting GSCs are expected to improve patient outcomes. We used a multistep in silico screening strategy to identify repurposed cand idate drugs against selected therapeutic molecu...
Source: Molecular Neurobiology - April 15, 2024 Category: Neurology Source Type: research
Preoperative neoadjuvant bevacizumab and temozolomide for newly diagnosed and resectable glioblastoma
(Source: Journal of Neuro-Oncology)
Source: Journal of Neuro-Oncology - April 15, 2024 Category: Cancer & Oncology Source Type: research
GSE263588 Comprehensive transcriptomic profiling of glioblastoma patient-derived primary tumor cell lines using bulk RNA-sequencing
Contributors : Sun H Paek ; Sanghyuk Lee ; Jong E Lee ; Yona KimSeries Type : Expression profiling by high throughput sequencingOrganism : Homo sapiensGlioblastoma multiforme (GBM) is a highly aggressive primary brain cancer with significant transcriptomic heterogeneity among patients. Our study aims to contribute to the field of personalized medicine for GBM patients by providing comprehensive transcriptomic profiles of GBM patients (N = 45) who underwent concurrent chemoradiotherapy with temozolomide at Seoul National University Hospital. Additionally, we include transcriptomic profiles of normal brain tissue obtained ...
Source: GEO: Gene Expression Omnibus - April 14, 2024 Category: Genetics & Stem Cells Tags: Expression profiling by high throughput sequencing Homo sapiens Source Type: research
Lidocaine attenuates TMZ resistance and inhibits cell migration by modulating the MET pathway in glioblastoma cells
Oncol Rep. 2024 May;51(5):72. doi: 10.3892/or.2024.8731. Epub 2024 Apr 12.ABSTRACTGlioblastoma multiforme (GBM) is the most aggressive type of malignant brain tumor. Currently, the predominant clinical treatment is the combination of surgical resection with concurrent radiotherapy and chemotherapy, using temozolomide (TMZ) as the primary chemotherapy drug. Lidocaine, a widely used amide‑based local anesthetic, has been found to have a significant anticancer effect. It has been reported that aberrant hepatocyte growth factor (HGF)/mesenchymal‑epithelial transition factor (MET) signaling plays a role in the progression o...
Source: Oncology Reports - April 12, 2024 Category: Cancer & Oncology Authors: Ming-Shan Chen Zhi-Yong Chong Cheng Huang Hsiu-Chen Huang Pin-Hsuan Su Jui-Chieh Chen Source Type: research
Cancers, Vol. 16, Pages 1485: Emerging Therapies for Glioblastoma
Megan Keniry
Glioblastoma is most commonly a primary brain tumor and the utmost malignant one, with a survival rate of approximately 12–18 months. Glioblastoma is highly heterogeneous, demonstrating that different types of cells from the same tumor can manifest distinct gene expression patterns and biological behaviors. Conventional therapies such as temozolomide, radiation, and surgery have limitations. As of now, there is no cure for glioblastoma. Alternative treatment methods to eradicate glioblastoma are discussed in this review, including targeted therapies to PI3K, NFKβ, JAK-STAT, CK2, ...
Source: Cancers - April 12, 2024 Category: Cancer & Oncology Authors: Stella Aim é Rios Stephanie Oyervides David Uribe Angelica Maree Reyes Victor Fanniel Jonathan Vazquez Megan Keniry Tags: Review Source Type: research
Temozolomide-associated blepharoconjunctivitis: a case report
Temozolomide (TMZ) is an effective oral alkylating agent used in treating glioblastoma multiforme (GBM) and high-grade gliomas. It works by introducing methyl groups into DNA, inhibiting cell division. A case ... (Source: BMC Ophthalmology)
Source: BMC Ophthalmology - April 12, 2024 Category: Opthalmology Authors: Tom Kornhauser and John D Pemberton Tags: Case Report Source Type: research
Deep-targeted gene sequencing reveals ARID1A mutation as an important driver of glioblastoma
CONCLUSION: The ARID1A gene is a critical predictive biomarker for glioma. Mutations at the ARID1A locus alter the stability of the SWI/SNF complex, leading to changes in transcriptional regulation in glioma cells. This contributes to an increased malignant phenotype of GBM and plays a pivotal role in mediating chemoresistance.PMID:38600891 | DOI:10.1111/cns.14698 (Source: CNS Neuroscience and Therapeutics)
Source: CNS Neuroscience and Therapeutics - April 11, 2024 Category: Neuroscience Authors: Menglin Xiao Xiaoteng Cui Can Xu Lei Xin Jixing Zhao Shixue Yang Biao Hong Yanli Tan Jie Zhang Xiang Li Jie Li Chunsheng Kang Chuan Fang Source Type: research
Deep-targeted gene sequencing reveals ARID1A mutation as an important driver of glioblastoma
CONCLUSION: The ARID1A gene is a critical predictive biomarker for glioma. Mutations at the ARID1A locus alter the stability of the SWI/SNF complex, leading to changes in transcriptional regulation in glioma cells. This contributes to an increased malignant phenotype of GBM and plays a pivotal role in mediating chemoresistance.PMID:38600891 | PMC:PMC11007544 | DOI:10.1111/cns.14698 (Source: CNS Neuroscience and Therapeutics)
Source: CNS Neuroscience and Therapeutics - April 11, 2024 Category: Neuroscience Authors: Menglin Xiao Xiaoteng Cui Can Xu Lei Xin Jixing Zhao Shixue Yang Biao Hong Yanli Tan Jie Zhang Xiang Li Jie Li Chunsheng Kang Chuan Fang Source Type: research
Advances in Radionuclide Therapies for Patients with Neuro-endocrine Tumors
AbstractPurpose of ReviewTo provide insights into the role of peptide receptor radionuclide therapy (PRRT) in patients with advanced neuroendocrine tumors (NET) and an overview of possible strategies to combine PRRT with locoregional and systemic anticancer treatments.Recent FindingsResearch on combining PRRT with other treatments encompasses a wide variety or treatments, both local (transarterial radioembolization) and systemic therapies, chemotherapy (i.e., capecitabine and temozolomide), targeted therapies (i.e., olaparib, everolimus, and sunitinib), and immunotherapies (e.g., nivolumab and pembrolizumab). Furthermore, ...
Source: Current Oncology Reports - April 10, 2024 Category: Cancer & Oncology Source Type: research
Hypoxic microenvironment-induced exosomes confer temozolomide resistance in glioma through transfer of pyruvate kinase M2
ConclusionIn the hypoxic microenvironment, glioma cells become resistant to TMZ due to the delivery of PKM2 by exosomes. Targeted modulation of exosomal PKM2 may be a promising strategy for overcoming TMZ resistance in glioma. (Source: Hormones and Cancer)
Source: Hormones and Cancer - April 10, 2024 Category: Cancer & Oncology Source Type: research
Ketogenic metabolic therapy in conjunction with standard treatment for glioblastoma: A case report
Oncol Lett. 2024 Mar 26;27(5):230. doi: 10.3892/ol.2024.14363. eCollection 2024 May.ABSTRACTGlioblastoma (GBM) is the most common primary malignant brain tumour in adults. The standard of care consists of surgical resection and concurrent chemoradiation, followed by adjuvant temozolomide chemotherapy. This protocol is associated with a median survival of 12-15 months, and <5% of patients survive >3 years. Ketogenic metabolic therapy (KMT) targets cancer cell metabolism by restricting glucose availability and evoking differential stress resistance and sensitization, which may augment the standard treatments and lead t...
Source: Oncology Letters - April 8, 2024 Category: Cancer & Oncology Authors: Matthew C L Phillips Ziad Thotathil Prashanth Hari Dass Fouzia Ziad Ben G Moon Source Type: research
